Merck’s KEYTRUDA^® (Pembrolizumab) Showed Statistically Significant Improvement in Disease-Free Survival Versus Placebo as Adjuvant Treatment for Patients with Stage IB-IIIA Non-Small Cell Lung Cancer Regardless of PD-L1 Expression

Merck announced that the Phase III KEYNOTE-091 trial investigating KEYTRUDA, Merck’s anti-PD-1 therapy, met one of its dual primary endpoints of disease-free survival for the adjuvant treatment of patients with stage IB-IIIA non-small cell lung cancer following surgical resection regardless of PD-L1 expression.